Debate Over Drug Ads—Lawmakers Push to Ban Direct-to-Consumer Advertising
Source: PharmaVoice
A new bill led by two independent senators seeks to ban direct-to-consumer (DTC) pharmaceutical advertising, arguing that promotions drive up drug costs and mislead patients. While some support the move as a step toward transparency, critics claim it could limit patient awareness and hinder innovation in healthcare marketing.
Chinese Biotechs Gain Ground—Out-Licensing to U.S. Partners Surges 11%
Source: FierceBiotech
Chinese biotech companies are increasingly out-licensing assets to U.S. firms, with deals rising 11%, according to a new Jefferies report. This trend reflects shifting market dynamics as Chinese innovators focus on global expansion, driven by domestic pricing pressures and a more constrained funding environment.
340B Program Under Scrutiny—Report Flags Billions of Hidden Medicaid Costs
Source: The Pharma Letter
A new analysis reveals that the 340B drug pricing program may be shifting billions in hidden costs to Medicaid and taxpayers. While originally designed to support safety-net providers, some misaligned incentives and duplicate discounts are creating financial burdens across the healthcare system.
